Neuroscientific Biopharmaceuticals Ltd (NSB) — Cash Flow-to-Debt Ratio
Neuroscientific Biopharmaceuticals Ltd (NSB) has a Cash Flow-to-Debt Ratio of -3.22x as of June 2025, meaning its operating cash flow of AU$-480.55K could theoretically repay -3% of its total liabilities (AU$149.22K) in one year. See Neuroscientific Biopharmaceuticals Ltd (NSB) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neuroscientific Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Neuroscientific Biopharmaceuticals Ltd across 10 annual periods. For the full cash flow conversion analysis, see Neuroscientific Biopharmaceuticals Ltd (NSB) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Neuroscientific Biopharmaceuticals Ltd. Check Neuroscientific Biopharmaceuticals Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.31x | AU$-941.33K | AU$149.22K | ▼ -1321.5% |
| 2024 | 0.52x | AU$44.25K | AU$85.68K | ▲ +113.4% |
| 2023 | -3.86x | AU$-2.30 Million | AU$597.36K | ▼ -23.2% |
| 2022 | -3.13x | AU$-6.94 Million | AU$2.22 Million | ▲ +73.1% |
| 2021 | -11.64x | AU$-2.60 Million | AU$223.41K | ▲ +54.8% |
| 2020 | -25.77x | AU$-2.28 Million | AU$88.53K | ▼ -14.4% |
| 2019 | -22.53x | AU$-1.41 Million | AU$62.48K | ▼ -245.6% |
| 2018 | -6.52x | AU$-497.91K | AU$76.39K | ▼ -50.9% |
| 2017 | -4.32x | AU$-186.42K | AU$43.15K | ▼ -501.2% |
| 2016 | -0.72x | AU$-87.76K | AU$122.12K | — |